Overview
I am dedicated to the treatment of hematologic malignancies through cellular therapies such as hematopoietic stem cell transplantation (HCT). My research focuses on strategies to reduce complications of HCT and ranges from preclinical studies using murine models of HCT to Phase 1 and Phase 2 clinical trials. Areas of interest include the role of the microbiota (the trillions of bacteria living in and on our bodies), nutrition, and exercise in modulating HCT outcomes such as graft-versus-host disease (GVHD) and infections. In addition to advancing new pharmacological and cellular immunotherapies in support of these goals, we also are developing mobile health technologies (mHealth) to monitor patients at home, both as part of our innovative home transplant program as well as to improve follow up care of all our patients when they return home after transplant.
Current Duke Appointments & Affiliations
Recent Scholarly Works
Patient-reported outcomes in clinical trials: lessons from the Blood and Marrow Transplant Clinical Trials Network.
Journal article Blood Adv · October 27, 2026 The Blood and Marrow Transplant Clinical Trials Network performs multicenter phase 2 and phase 3 clinical trials and has incorporated patient-reported outcome (PRO) measures into study protocols since its inception. As with clinical data, collection and an ... Full text Link to item CiteGraft-versus-host disease prophylaxis shapes T cell biology and immune reconstitution after hematopoietic cell transplant.
Journal article Sci Transl Med · October 21, 2026 Successful hematopoietic cell transplant requires immunosuppression to prevent graft-versus-host disease (GVHD), a lethal, T cell-mediated complication. The phase 3 BMT CTN 1703 trial demonstrated superior GVHD-free/relapse-free survival for posttransplant ... Full text Link to item CiteSociodemographic factors and timing of allogeneic hematopoietic stem cell transplantation in myeloproliferative neoplasms.
Journal article Bone Marrow Transplant · June 2026 Full text Link to item CiteRecent Grants
A Randomized Phase 2 Trial to Evaluate Prebiotic Intervention in Allogeneic Hematopoietic Stem Cell Transplantation
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2020 - 2025Viral Oncology Training Grant
Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 1980 - 2025A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir (LET) prophylaxis when extended from 100days to 200 days post-transplant in cytomegalovirus (CMV) seropositive recipients (R+)
Clinical TrialPrincipal Investigator · Awarded by Merck Sharp & Dohme · 2019 - 2024View All Grants